Bascom Palmer Eye Institute Presents Research on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026
At the 2026 ARVO Annual Meeting, researchers from Bascom Palmer Eye Institute will present four posters on Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT), focusing on its application for treating infectious keratitis. The therapy is being commercialized by Provectus’s subsidiary, VisiRose. Key findings from the REAGIR trial, which compared RB-PDAT with standard treatment methods, along with in vitro studies on the effects of corneal biochemical environments on treatment outcomes, will be highlighted.
KNOXVILLE, Tenn., May 04, 2026 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT), a clinical-stage biopharmaceutical company developing proprietary synthetic small molecule rose bengal sodium (“RBS”)-based medicines, notes that researchers from Bascom Palmer Eye Institute (“BPEI”) at the University of Miami will present four posters on rose bengal photodynamic antimicrobial therapy (“RB-PDAT”) at the 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology (“ARVO”), to be held May 3–7 in Denver, Colorado.